BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...

Coronaviruses not only use the machinery of the human cells they infect: they modify it to achieve optimal conditions to produce viral proteins and thus spread more quickly. This is the main ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

CDI-988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections; ...

Asahi Kasei has agreed a €780 million (around $920 million) price tag for Wuppertal-based Aicuris, which is hoping for FDA ...

In 2022, mpox infections surged in the United States and other Western countries, showing that a viral illness long considered endemic in central and ...

Scientists may have found a promising new treatment for Covid-19 after an experimental oral antiviral drug demonstrated the ability to prevent the coronavirus from replicating, the National Institutes ...

Adam Kovalčík, age 19, innovated a cheaper, faster way to produce an antiviral drug. Galidesivir targets RNA viruses like COVID-19, Ebola, and Zika but hasn't completed clinical trials. Kovalčík won a ...

A common hallmark of viral genome replication is a high mutation rate, which can aid in their ability to evade new treatments and acquire resistance to once-effective antiviral medications. Now, a new ...

Influenza is an acute respiratory disease that causes epidemics and pandemics in the human population of temperate regions. Influenza epidemics occur every year during the winter months, affecting ...